Conscious Dying/Conscious Living: Ketamine-Assisted Psychotherapy

This randomised, double-blind, placebo-controlled trial (n=120) will investigate the effects of Ketamine-Assisted Psychotherapy (KAP) on patients with terminal illnesses.

Administered by The Ketamine Research Foundation, the study will take place at five locations and involve 18 subjects at each site. Participants will undergo two separate intramuscular ketamine sessions accompanied by psychotherapeutic support over 4-6 weeks.

Assessments will measure changes in anxiety levels and distress related to death and dying. A naturalistic comparator group will also undergo assessments and have the option for crossover KAP treatment.

The primary outcome measures are changes in the State-Trait Anxiety Inventory (trait assessment only) and the Death and Dying Distress Scale. The study aims to evaluate the efficacy of KAP in palliative and hospice care settings.

Topic Palliative Care
Compound Ketamine Placebo
Country United States of America
Visit trial

Trial Details



Trial Number

Data attribution

A large set of the trials in our database are sourced from ClinicalTrials.gov (CTG). We have modified these post to display the information in a more clear format or to correct spelling mistakes. Our database in actively updated and may show a different status (e.g. completed) if we have knowledge of this update (e.g. a published paper on the study) which isn't reflected yet on CTG. If a trial is not sourced from CTG, this is indicated on this page and you can follow the link to the alternative source of information.